Immunogenicity and Safety of Hecolin® in HIV Positive/Negative Adults and in Children
NCT ID: NCT06306196
Last Updated: 2025-04-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
1040 participants
INTERVENTIONAL
2024-04-04
2026-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of the Safety and Tolerance of Immunotherapy With Autologous, Ex-Vivo Expanded, HIV-Specific Cytotoxic T-Cells in HIV-Infected Patients With CD4+ Counts Between 100-400/mm3
NCT00000756
Safety of and Immune Response to an Adenoviral HIV-1 Vaccine in Healthy Adults
NCT00618605
Immunogenicity and Safety of Inactivated Hepatitis A Vaccine in HIV-infected People
NCT06576024
Interluekin-7 to Treat HIV-Infected People Receiving Antiretroviral Treatment
NCT00105417
Safety and Immune Response to a Recombinant Adenovirus HIV-1 Vaccine in Healthy Adults
NCT00695877
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
A total of 860 participants will be enrolled in the main study and will be divided into 4 age strata; 18-45 years (Cohort A), 12-17 years (Cohort B), 6-11 years (Cohort C) and 2-5 years (Cohort D) having 410, 175, 175 and 100 participants respectively. Cohort A will be further divided into Arm A1 and A2 having 232 HIV -ve and 178 HIV +ve participants respectively. All participants in cohort A will receive intramuscular injection of 3 doses of 30 µg Hecolin® at 0, 1 and 6 months. Cohort B will be further divided into Arm B1, B2 and B3 having 70, 70 and 35 participants respectively. Arm B1 will receive intramuscular injection of 3 doses of 30 µg Hecolin® at 0, 1 and 6 months. Arm B2 will receive intramuscular injection of 2 doses of 30 µg Hecolin® at 0 and 6 months while Arm B3 will receive intramuscular injection of comparator (placebo) intramuscularly at 0, 1 and 6 months. Similarly, Cohort C will be further divided into Arm C1, C2 and C3 having 70, 70 and 35 participants respectively. Arm C1 will receive intramuscular injection of 3 doses of 30 µg Hecolin® at 0, 1 and 6 months. Arm C2 will receive intramuscular injection of 2 doses of 30 µg Hecolin® at 0 and 6 months while Arm C3 will receive intramuscular injection of comparator (placebo) intramuscularly at 0, 1 and 6 months. Cohort D will be further divided into Arm D1, D2 and D3 having 40, 40 and 20 participants respectively. Arm D1 will receive intramuscular injection of 3 doses of 30 µg Hecolin® at 0, 1 and 6 months. Arm D2 will receive intramuscular injection of 2 doses of 30 µg Hecolin® at 0 and 6 months while Arm D3 will receive intramuscular injection of comparator (placebo) intramuscularly at 0,1 and 6 months.
In the main study a total of 6 blood samples for immunogenicity will be collected from all participants at Day 0 (baseline), one month after first vaccination, one month after second vaccination, 6 months after first vaccination, one month after third vaccination, and at 6 months after third vaccination.
Blood samples will be collected at screening and one month after third vaccination from the HIV + arm to document CD4 T cells and HIV Viral load.
Out of the 860 participants enrolled in the main study, 2 additional blood samples after reconsent for the 2-year long term follow up period will be collected at V8 (12 months after 3rd dose) and V9 (24 months after 3rd dose) from any 100 HIV negative adults in Cohort A and from participants in Hecolin arms in Cohorts B, C and D (B1, B2, C1, C2, D1, and D2) for immunogenicity assessment. In the additional 0-1-month dose schedule component/arm, a total of 4 blood samples will be collected from all participants at V2 (Day 0), V3 (28 days after 1st dose), V4 (28 days after 2nd dose), V5 (6 months after 2nd dose), and 2 additional samples will be collected from participants in Hecolin arms in Cohorts B, C and D (B4, C4, and D4) at V6 (12months after 2nd dose), and V7 (24 months after 2nd dose) for immunogenicity assessment.
All participants will be observed at the study site for 30 minutes after each Investigational Product (IP) injection for any reactogenicity events. Local and systemic solicited adverse events will be recorded in a diary card during 7 days after each IP dose while unsolicited adverse events will be recorded during the 4 weeks after each IP injection. Serious adverse events (SAEs), Medically attended adverse events (MAAEs) and Adverse of special interest (AESI) will be recorded during the entire study period i.e., until 6 months post last dose.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
QUADRUPLE
For children cohorts, the PI, study staff, and child participants will be blinded as to receipt of the study vaccine or placebo. The unblinded pharmacist preparing the IP as well as the unblinded vaccinator will not be involved in the safety assessment of participants and will be instructed not to comment on the experimental agent to study staff.
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group A1 (Three doses of Hecolin®; HIV negative adults aged 18-45 years)
Three doses of Hecolin® Recombinant Hepatitis E Vaccine administered at 0, 1 and 6 months to HIV negative participants, age 18-45 years old, 232 participants
Hecolin® Recombinant Hepatitis E Vaccine
30㎍/dose, 0.5mL administered intramuscularly
Group A2 (Three doses of Hecolin®; HIV positive adults aged 18-45 years)
Three doses of Hecolin® Recombinant Hepatitis E Vaccine, administered at 0, 1 and 6 months, to HIV positive participants, age 18-45 years old, 178 participants
Hecolin® Recombinant Hepatitis E Vaccine
30㎍/dose, 0.5mL administered intramuscularly
Group B1 (Three doses of Hecolin®; healthy adolescents aged 12-17 years)
Three doses of Hecolin® Recombinant Hepatitis E Vaccine, administered at 0, 1 and 6 months, to age 12-17 years old, 70 participants
Hecolin® Recombinant Hepatitis E Vaccine
30㎍/dose, 0.5mL administered intramuscularly
Group B2 (Two doses of Hecolin®; healthy adolescents aged 12-17 years)
Two doses of Hecolin® Recombinant Hepatitis E Vaccine, administered at 0, 1 and 6 months) and one dose of Placebo, administered at 1-month timepoint, to age 12-17 years old, 70 participants
Hecolin® Recombinant Hepatitis E Vaccine
30㎍/dose, 0.5mL administered intramuscularly
Isotonic Sodium Chloride injection
0.5mL administered intramuscularly
Group B3 (Placebo; healthy adolescents aged 12-17 years)
Three doses of Placebo, administered at 0, 1 and 6 months, to age 12-17 years old, 35 participants
Isotonic Sodium Chloride injection
0.5mL administered intramuscularly
Group C1 (Three doses of Hecolin®; healthy children aged 6-11 years)
Three doses of Hecolin® Recombinant Hepatitis E Vaccine, administered at 0, 1 and 6 months, to age 6-11 years old, 70 participants
Hecolin® Recombinant Hepatitis E Vaccine
30㎍/dose, 0.5mL administered intramuscularly
Group C2 (Two doses of Hecolin®; healthy children aged 6-11 years)
Two doses of Hecolin® Recombinant Hepatitis E Vaccine, administered at 0 and 6 months and one dose of Placebo, administered at 1-month timepoint, to age 6-11 years old, 70 participants
Hecolin® Recombinant Hepatitis E Vaccine
30㎍/dose, 0.5mL administered intramuscularly
Isotonic Sodium Chloride injection
0.5mL administered intramuscularly
Group C3 (Placebo; healthy children aged 6-11 years)
Three doses of Placebo, administered at 0, 1 and 6 months, to age 6-11 years old, 35 participants
Isotonic Sodium Chloride injection
0.5mL administered intramuscularly
Group D1 (Three doses of Hecolin®; healthy children aged 2-5 years)
Three doses of Hecolin® Recombinant Hepatitis E Vaccine, administered at 0, 1 and 6 months, to age 2-5 years old, 40 participants
Hecolin® Recombinant Hepatitis E Vaccine
30㎍/dose, 0.5mL administered intramuscularly
Group D2 (Two doses of Hecolin®; healthy children aged 2-5 years)
Two doses of Hecolin® Recombinant Hepatitis E Vaccine, administered at 0 and 6 months and of Placebo, administered at 1-month timepoint, to age 2-5 years old, 40 participants
Hecolin® Recombinant Hepatitis E Vaccine
30㎍/dose, 0.5mL administered intramuscularly
Isotonic Sodium Chloride injection
0.5mL administered intramuscularly
Group D3 (Placebo; healthy children aged 2-5 years)
Three doses of Placebo, administered at 0, 1 and 6 months, to age 2-5 years old, 40 participants
Isotonic Sodium Chloride injection
0.5mL administered intramuscularly
Group B4 (Two doses of Hecolin®; healthy children aged 12-17 years)
Two doses of Hecolin® Recombinant Hepatitis E Vaccine, administered at 0, and 1 month, to age 12-17 years old, 50 participants
Hecolin® Recombinant Hepatitis E Vaccine
30㎍/dose, 0.5mL administered intramuscularly
Group B5 (Placebo; healthy children aged 12-17 years)
Two doses of Placebo, administered at 0, and 1 month, to age 12-17 years old, 10 participants
Isotonic Sodium Chloride injection
0.5mL administered intramuscularly
Group C4 (Two doses of Hecolin®; healthy children aged 6-11 years)
Two doses of Hecolin® Recombinant Hepatitis E Vaccine, administered at 0, and 1 month, to age 6-11 years old, 50 participants
Hecolin® Recombinant Hepatitis E Vaccine
30㎍/dose, 0.5mL administered intramuscularly
Group C5 (Placebo; healthy children aged 6-11 years)
Two doses of Placebo, administered at 0, and 1 month, to age 6-11 years old, 10 participants
Isotonic Sodium Chloride injection
0.5mL administered intramuscularly
Group D4 (Two doses of Hecolin®; healthy children aged 2-5 years)
Two doses of Hecolin® Recombinant Hepatitis E Vaccine, administered at 0, and 1 month, to age 2-5 years old, 50 participants
Hecolin® Recombinant Hepatitis E Vaccine
30㎍/dose, 0.5mL administered intramuscularly
Group D5 (Placebo; healthy children aged 2-5 years)
Two doses of Placebo, administered at 0, and 1 month, to age 2-5 years old, 10 participants
Isotonic Sodium Chloride injection
0.5mL administered intramuscularly
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Hecolin® Recombinant Hepatitis E Vaccine
30㎍/dose, 0.5mL administered intramuscularly
Isotonic Sodium Chloride injection
0.5mL administered intramuscularly
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Participants/Parent(s)/LAR who have voluntarily given informed consent/assent,
3. Participants/Parent(s)/LAR willing to follow the study procedures and available for the entire duration of the study and agrees to the collection of all biospecimens,
4. HIV negative,
5. Not pregnant,
6. Agreement to practice effective contraception for female participants of childbearing potential and non-sterile males until at least 8 months after the first vaccination.
7. Has practiced adequate contraception or has abstained from all activities that could result in pregnancy for at least 28 days prior to the first dose of vaccine, and
8. Female participant not currently breastfeeding.
1. Adults 18-45 years living with HIV on anti-retroviral (ARV) treatment and willing to have CD4 and viral load measured as per protocol,
2. Able to provide a voluntary signed informed consent,
3. Participants willing to follow the study procedures of the study and available for the entire duration of the study and agrees to the collection of all biospecimens,
4. Agreement to practice effective contraception for female participants of childbearing potential and non-sterile males until at least 3 months after the last vaccination.
5. Has practiced adequate contraception or has abstained from all activities that could result in pregnancy for at least 28 days prior to the last dose of vaccine, and
6. Female participant is currently not breastfeeding.
Exclusion Criteria
1. Has received any hepatitis E vaccine in the past,
2. Febrile illness (body temperature ≥ 38°C) or acute illness within 3 days prior to the study vaccination,
3. Known history or allergy to study vaccine components and/or excipients or other medications, or any other allergies or medical history deemed by the investigator to increase the risk of an adverse event if they were to participate in the trial (e.g., Guillain-Barre Syndrome),
4. Major congenital abnormalities which in the opinion of the investigator may affect the participant's participation in the study,
5. Known history of immune function disorders including immunodeficiency diseases (known HIV infection or other immune function disorders) and lupus,
6. Chronic use of systemic steroids (\>2 mg/kg/day or \>20 mg/day prednisone equivalent for periods exceeding 10 days), cytotoxic or other immunosuppressive drugs within the past 6 weeks,
7. Any abnormality or chronic disease which in the opinion of the investigator might be detrimental to the safety of the participant and interfere with the assessment of the study objectives,
8. Behavioral or cognitive impairment, chronic substance abuse, or psychiatric disease or neural disorders, that, in the opinion of the investigator, could interfere with the participant's ability to participate in the trial,
9. History of splenectomy,
10. History of thrombocytopenia and/or thrombosis, myocarditis or pericarditis or any other significant cardiac condition,
11. With a known bleeding diathesis or any condition that may be associated with a prolonged bleeding time resulting in contraindication for IM injections/blood extractions.,
12. Receipt of blood or blood-derived products in the past 3 months,
13. Receipt of other vaccines from 4 weeks prior to test vaccination or planned to receive any vaccine within 4 weeks of last dose of study vaccine,
14. Concomitantly enrolled or scheduled to be enrolled in another trial,
15. Research staff involved with the clinical study or family/household members of research staff,
16. Body mass index (BMI) of ≥ 40 in adults and for children a BMI- index-for-age is ≥95th percentile, at the time of the screening visit, or
An individual who meets any of the following criteria will be excluded from participation in this study:
1. Has received any hepatitis E vaccine in the past,
2. Newly diagnosed HIV-positive (diagnosed on screening) on ARVs for 0-4 weeks (Note: These participants can be re-screened and enrolled once they have been on ARVs for 4 weeks),
3. Febrile illness (body temperature ≥ 38°C) or acute illness within 3 days prior to the study vaccination,
4. Serious adverse reaction to any vaccine, or any component of the investigational vaccine, including a history of anaphylaxis and symptoms of a severe allergic reaction and history of allergies in the past,
5. Current hospitalization,
6. History of inherited blood disorders, heparin-induced thrombocytopenia, or thromboembolic disorders,
7. History of any blood product transfusion up to 6 months before enrolment,
8. Receipt of other vaccines from 4 weeks prior to test vaccination or planned to receive any vaccine within 4 weeks of last dose of study vaccine
9. Currently taking anti-coagulation therapy, or chronic aspirin in the past 3 months,
10. Pregnant or breastfeeding women throughout the study period,
11. Extreme obesity (defined as BMI of 40 kg/m2 or higher),
12. Chronic kidney disease requiring dialysis,
13. Liver disease (Note mild chronic liver disease is not an exclusion criterion),
14. Participants with acquired or hereditary immunodeficiencies other than HIV,
15. History of hereditary, idiopathic, or acquired angioedema,
16. No spleen or functional asplenia,
17. Platelet disorder or other bleeding disorder that may cause injection contraindication,
18. Chronic use (more than 14 continuous days) of any medications that may be associated with impaired immune responsiveness including, but not limited to, systemic corticosteroids exceeding 10 mg/day of prednisone equivalent, allergy injections, immunoglobulin, interferon, or immunomodulators. The use of low dose topical, ophthalmic, inhaled, and intranasal steroid preparations will be permitted,
19. According to the judgement of the investigator, the participant has any other factors that might interfere with the results of the clinical trial or pose additional risk due to participation in the study,
20. Assessed by the Investigator to be unable or unwilling to comply with the requirements of the protocol
2 Years
45 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Xiamen Innovax Biotech Co., Ltd
INDUSTRY
Bill and Melinda Gates Foundation
OTHER
International Vaccine Institute
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Tarun Saluja
Role: PRINCIPAL_INVESTIGATOR
International Vaccine Institute
Sanet Aspinall
Role: PRINCIPAL_INVESTIGATOR
Ardent Consulting (Pty) Ltd
Elizabeth Hellström
Role: PRINCIPAL_INVESTIGATOR
Be Part Research
Maphoshane Nchabeleng
Role: PRINCIPAL_INVESTIGATOR
MeCRU Clinical Research Unit
Essack Mitha
Role: PRINCIPAL_INVESTIGATOR
Newtown Clinical Research Centre
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
MeCRU Clinical Research Unit
Ga-Rankuwa, , South Africa
Newtown Clinical Research Centre
Johannesburg, , South Africa
Be Part Research
Paarl, , South Africa
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IVI Hecolin S001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.